Lp(a) At-Home and Finger-Prick Testing: Ranges, Methods, and Next Steps

Why Lp(a) Is a Once-in-a-Lifetime Test Worth Getting Right

Lp(a) is almost entirely determined by the LPA gene locus. Diet, exercise, and standard lipid-lowering drugs change it very little. Because the value is stable across a person's lifetime, a single accurate measurement is sufficient for most people, and the American College of Cardiology and American Heart Association both recommend it as part of cardiovascular risk assessment.

The 2018 ACC/AHA Cholesterol Guideline states: "Measurement of Lp(a) may be reasonable in patients at intermediate or high 10-year cardiovascular risk to guide clinical decision-making." [1] Getting that single measurement right, meaning in the correct units with a validated assay, determines whether you are categorized as low, intermediate, or high risk.

How Common Is Elevated Lp(a)?

Roughly one in five adults worldwide carries an Lp(a) above 50 mg/dL, the threshold most guidelines use to define elevated risk. [2] In individuals of South Asian or Black African ancestry, prevalence is higher, reaching 30 to 40 percent in some population studies. [3] These numbers make Lp(a) one of the most common inherited cardiovascular risk factors, yet it remains vastly under-tested compared to LDL-C.

Why Standard Lipid Panels Usually Miss It

A routine lipid panel ordered at a primary care visit reports total cholesterol, LDL-C, HDL-C, and triglycerides. Lp(a) is not included. You must specifically request it. Many insurance plans cover the test once, particularly when a first-degree relative has premature coronary artery disease or aortic stenosis, but coverage is inconsistent, which is one reason at-home testing has grown in popularity.

Lp(a) Normal Range and Optimal Levels Explained

The "normal" Lp(a) range depends on which unit your lab uses and which guideline you reference. This is one of the most common sources of patient confusion, and it matters clinically.

Units: mg/dL vs. Nmol/L

Labs report Lp(a) in either mass units (mg/dL) or molar units (nmol/L). The European Atherosclerosis Society (EAS) strongly prefers nmol/L because Lp(a) particles vary in size based on the number of kringle IV type-2 repeats in apolipoprotein(a). A fixed conversion factor between mg/dL and nmol/L does not exist, which can shift a borderline result from "acceptable" to "elevated" or vice versa depending on the assay. [4]

If your result comes back in mg/dL and you want to compare it to nmol/L-based guidelines, the rough (imprecise) approximation is: nmol/L value is approximately 2 to 2.5 times the mg/dL value, but this is not reliable at individual level. Request a lab that reports in nmol/L if you have a choice.

Key Thresholds From Named Guidelines

| Guideline | Threshold | Risk Designation | |---|---|---| | ESC/EAS 2019 Dyslipidaemia Guidelines | >30 mg/dL (>75 nmol/L) | Elevated cardiovascular risk | | ACC/AHA 2018 Cholesterol Guideline | >50 mg/dL (>125 nmol/L) | High risk; consider more intensive LDL-C lowering | | EAS Consensus Statement 2022 | >70 mg/dL (>180 nmol/L) | Very high risk; prioritize emerging Lp(a)-lowering therapies | | Canadian Cardiovascular Society 2021 | >50 nmol/L | Intermediate risk reclassification trigger |

The ESC/EAS 2019 Dyslipidaemia Guidelines specify: "An Lp(a) >180 mg/dL (430 nmol/L) carries a lifetime cardiovascular risk equivalent to familial hypercholesterolaemia." [5] That is a specific numeric benchmark, not a vague statement about "high levels."

What Is Truly Optimal?

Population data from the Copenhagen City Heart Study (N=69,644) found that Lp(a) below approximately 10 mg/dL (roughly 25 nmol/L) is associated with the lowest observed ASCVD event rates. [6] Most longevity-medicine practitioners set an aspirational target of <30 nmol/L based on Mendelian randomization studies, which show a roughly linear relationship between genetically predicted Lp(a) and coronary artery disease risk. [7]

No drug currently approved in the United States or European Union reliably lowers Lp(a) to that target, but that context makes the number actionable: it defines the therapeutic gap that pelacarsen, olpasiran, and zerlasiran are trying to close in ongoing Phase 3 trials.

At-Home Lp(a) Testing: Venous Kits, Finger-Prick Cards, and What to Expect

Most at-home Lp(a) tests fall into two categories: dried blood spot (DBS) finger-prick cards and mail-in venous draw kits. A third option, ordering a traditional lab draw through a direct-to-consumer (DTC) platform without a clinic visit, is also widely available.

Dried Blood Spot and Finger-Prick Cards

DBS cards collect a few drops of capillary blood from a fingertip lancet onto filter paper. They are then mailed to a CLIA-certified reference lab. Published validation data for DBS-based lipid testing show strong correlation with venous samples for total cholesterol and HDL-C. [8] Lp(a) by DBS is technically feasible; however, as of 2025, only a small number of commercial DBS assays have published analytical validation specifically for Lp(a) in nmol/L.

Key practical points for DBS collection:

• Warm your hand for 2 to 3 minutes before lancing. Cold fingers produce insufficient blood flow and force a second lancet stick.
• Fill all required circles completely. Partially filled spots cause underreporting of analyte concentration.
• Allow the card to air-dry for at least 30 minutes before sealing in the provided foil pouch.
• Ship within 5 days. Heat and humidity degrade dried samples.

If the card's accompanying report is in mg/dL only, ask the lab whether an nmol/L-calibrated isoform-independent assay was used. This question directly affects whether the result meets EAS quality standards. [4]

Mail-In Venous Draw Kits

Some DTC companies send a kit that includes a fine-gauge needle, a collection tube, and a prepaid return mailer. The patient or a partner performs a small venous stick, typically at the antecubital fossa, and ships the tube refrigerated. These samples usually run on the same automated immunoassay platforms as hospital labs, so analytical validity is higher than most DBS methods for Lp(a).

Companies that route samples to certified reference labs (Quest Diagnostics, Labcorp, or equivalent) typically use a particle-enhanced turbidimetric immunoassay (PETIA) or enzyme-linked immunosorbent assay (ELISA). The EAS Consensus Statement recommends isoform-insensitive assays calibrated to WHO/IFCC secondary reference material. [4]

DTC Lab-Order Platforms (Clinic-Free Venous Draw)

Platforms such as Marek Health, Function Health, and direct-order services through Quest or Labcorp allow a person to purchase a lab order online and walk into a patient service center without a physician's requisition. The blood draw is performed by a trained phlebotomist under controlled conditions. For Lp(a), this option provides the highest analytical reliability of the three at-home pathways because:

1. Venous whole blood avoids DBS dilution and hematocrit variability.
2. The sample is processed fresh, not dried.
3. Most reference labs running these panels use isoform-insensitive Lp(a) assays.

Cost without insurance ranges from roughly $30 to $90 depending on the platform and whether Lp(a) is bundled with a cardiovascular panel.

HealthRX At-Home Lp(a) Method Selection Framework:

| Collection Method | Analytical Reliability | Convenience | Recommended For | |---|---|---|---| | DBS finger-prick card | Moderate (validate assay type first) | Highest | Screening; follow-up if DTC unavailable | | Mail-in venous kit | High (if PETIA/ELISA on reference platform) | High | Most users wanting clinic-free accuracy | | DTC phlebotomy walk-in | Highest | Moderate (requires travel to draw site) | Anyone with borderline or prior abnormal result | | Physician-ordered hospital lab | Highest | Low (requires appointment) | Confirmed high Lp(a); pre-treatment baseline |

Assay Quality: What Makes an Lp(a) Test Clinically Valid

Not all Lp(a) assays are equal. This is a point that lab companies rarely advertise clearly, but it can change your result by a factor of two.

Isoform Sensitivity Problem

Apolipoprotein(a) has a variable number of kringle IV type-2 (KIV-2) repeat domains. Older antibody-based assays bind to these repeats, so a person with more repeats (lower Lp(a) mass, smaller particles) reads falsely high, while someone with fewer repeats reads falsely low. Isoform-insensitive assays use antibodies targeting non-repeated epitopes and avoid this artifact. [9]

The EAS 2022 Consensus Statement specifically states: "Lp(a) should be measured using an isoform-insensitive assay and reported in nmol/L." [4] When you receive your at-home kit results, ask or check the report documentation for confirmation that the assay is isoform-independent.

Reference Standardization

The WHO/IFCC reference material (SRM 2B) standardizes Lp(a) assays globally. Labs not calibrated to this standard may report values 20 to 40 percent higher or lower than a reference center. Before comparing two Lp(a) results from different labs, confirm both used the same calibrator.

Factors That Affect Your Lp(a) Result

Lp(a) is largely genetic, but several physiological states can shift measurements enough to misclassify borderline results.

Conditions That Raise Lp(a) Transiently

• Acute inflammation and infection (Lp(a) behaves as a weak acute-phase reactant)
• Severe hypothyroidism; TSH above 10 mU/L can raise Lp(a) by 20 to 30 percent [10]
• End-stage renal disease and nephrotic syndrome
• Menopause transition (estrogen suppresses hepatic Lp(a) synthesis; its withdrawal raises levels by 10 to 25 percent) [11]

Conditions and Drugs That Lower Lp(a)

• Hormonal estrogen therapy lowers Lp(a) by 20 to 30 percent in postmenopausal women. [11] This is one reason women on HRT may have different Lp(a) values than their pre-menopausal sisters.
• PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by 20 to 30 percent. [12] The FOURIER trial (N=27,564) showed evolocumab reduced Lp(a) by a median of 26.9 percent, though the primary endpoint was LDL-C driven. [13]
• Niacin lowers Lp(a) by 20 to 30 percent but did not reduce cardiovascular events in AIM-HIGH (N=3,414) or HPS2-THRIVE (N=25,673). [14]
• Statins do not lower Lp(a) and may raise it by approximately 10 percent. [15]

Does Fasting Matter?

Lp(a) is not meaningfully affected by food intake. You do not need to fast before an Lp(a) test, though most cardiovascular panels that include LDL-C do require fasting. If you are ordering Lp(a) alone or checking whether a kit requires fasting, Lp(a) specifically does not.

Interpreting Your At-Home Result: A Step-by-Step Guide

Step 1: Confirm the Units

Find whether your result is in mg/dL or nmol/L. If mg/dL, note that the conversion to nmol/L is approximate and isoform-dependent.

Step 2: Apply the Correct Threshold

Use the ESC/EAS 2019 cut-off of 75 nmol/L (30 mg/dL) as a starting point for any elevated risk discussion. Use 125 nmol/L (50 mg/dL) for the ACC/AHA high-risk designation.

Step 3: Put It in Context of Your Global ASCVD Risk

An Lp(a) of 90 nmol/L in a 35-year-old non-smoker with optimal blood pressure means something different than the same value in a 58-year-old with hypertension and a 15-percent 10-year ASCVD risk score. The EAS recommends that Lp(a) elevation be used to reclassify intermediate-risk patients to high risk, triggering more aggressive LDL-C targets. [5]

Step 4: Verify Assay Quality Before Acting

If the report does not specify isoform-insensitive methodology, consider repeating at a reference lab before making major treatment decisions. A borderline result on a substandard assay is not a reliable basis for long-term statin intensification.

Step 5: Share the Result With a Clinician

Elevated Lp(a) changes management. The standard of care is to intensify LDL-C lowering (since LDL-C reduction reduces absolute event risk even when Lp(a) remains elevated), counsel on lifestyle risk factors, and discuss whether clinical trial enrollment for Lp(a)-specific therapies is appropriate.

Emerging Therapies: Why Testing Now Still Matters

Three RNA-based agents targeting hepatic Lp(a) synthesis are in late-stage trials as of 2025:

• Pelacarsen (antisense oligonucleotide, Novartis): Phase 3 Lp(a)HORIZON trial (NCT04023552) enrolled patients with established ASCVD and Lp(a) >70 mg/dL. Pelacarsen reduced Lp(a) by approximately 80 percent in Phase 2. [16]
• Olpasiran (small interfering RNA, Amgen): OCEAN(a)-DOSE trial (N=281) showed dose-dependent Lp(a) reductions of up to 97 percent at 52 weeks. [17] Phase 3 OCEAN(a) outcomes trial is ongoing.
• Zerlasiran (siRNA, Silence Therapeutics): Phase 2 ALPACAR-360 trial reported up to 94 percent Lp(a) reduction with quarterly dosing. [18]

Knowing your baseline Lp(a) now positions you to qualify for trials, access therapies if they gain FDA approval, and give your clinician a pre-treatment reference value.

Cascade Testing: Should Family Members Be Tested?

Because Lp(a) is largely determined by LPA gene variants inherited in an autosomal codominant pattern, first-degree relatives of a person with Lp(a) above 125 nmol/L have approximately a 50 percent probability of also carrying elevated Lp(a). [2] The EAS Consensus Statement recommends cascade testing of first-degree relatives when an index case has very high Lp(a). [4]

At-home testing makes this practical. A sibling or adult child can order a DTC kit without a clinic visit, generating a result in 7 to 14 days.

Special Populations: Considerations for Sex, Ancestry, and Age

Women and Hormonal Transitions

Lp(a) rises after menopause in most women. A woman who tested low-normal at age 40 may be in the elevated range by age 55 without any genetic change. If cardiovascular risk assessment occurs peri-menopausally, repeating Lp(a) after menopause is reasonable. The European Menopause and Andropause Society notes that menopausal hormone therapy with oral estradiol reduces Lp(a) and may partially offset this rise. [11]

Ancestry and Baseline Risk

Individuals of West African ancestry have higher median Lp(a) levels and are more likely to carry large numbers of KIV-2 repeats. This makes isoform-insensitive assay selection even more important for these individuals, because isoform-sensitive assays disproportionately overestimate Lp(a) mass in populations with longer apolipoprotein(a) isoforms. [9]

Pediatric Testing

The National Lipid Association recommends universal lipid screening between ages 9 and 11. Lp(a) is not universally included, but cascade testing should include children of a parent with familial hypercholesterolaemia (FH) because FH plus elevated Lp(a) substantially amplifies lifetime risk. [3] At-home kits exist for pediatric finger-prick collection, though a pediatrician's involvement in result interpretation is appropriate.